루푸스 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the lupus market size was valued at USD 4.22 billion in 2025 and is estimated to grow from USD 4.67 billion in 2026 to reach USD 7.66 billion by 2031, at a CAGR of 10.42% during the forecast period (2026-2031).

This report is Segmented by Disease Type (SLE, CLE, Others), Treatment Type (Corticosteroids, Immunosuppressives, Biologics, Antimalarials, Antihypertensives, Others), Diagnosis (Laboratory Tests, Biopsy, Imaging, Others), End User (Hospitals, Specialty Clinics, Homecare, Diagnostic Labs), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Lupus Market Trends and Insights

Rising Prevalence and Earlier Lupus Detection

As testing access improves, clinicians are diagnosing lupus earlier, increasing the number of patients entering treatment before irreversible organ damage occurs. Underdiagnosis remains a challenge in regions like South and Southeast Asia, Sub-Saharan Africa, and Latin America, but advancements in testing infrastructure are expected to address this issue. Tools such as serum Raman spectroscopy and deep-learning classifiers are expediting confirmation processes, reducing delays between symptom onset and treatment. Electronic health record dashboards are also helping providers close follow-up gaps, further supporting market growth by expanding the treated population.

Shift Toward Targeted Biologics and Steroid-Sparing Treatment

The lupus market is shifting towards targeted biologics and reduced steroid use, driven by updated 2025 treatment guidelines emphasizing early biologic initiation. This trend is increasing demand for therapies like belimumab, anifrolumab, and voclosporin. China's 2025 guideline update expanded biologic adoption and introduced JAK inhibitors, reflecting broader global acceptance. Real-world evidence shows biomarker-guided telitacicept achieves higher response rates and greater corticosteroid reduction compared to standard treatments, making advanced therapies more defensible to payers by reducing complications.

High Lifetime Treatment Cost and Access Barriers

High treatment costs continue to restrict the lupus market, despite strong clinical evidence supporting advanced therapies. In the U.S., annual biologic therapy costs often exceed USD 30,000. A 2025 analysis showed that 15.4% of patients faced financial instability, 8.2% encountered transportation challenges, and 12% lacked insurance coverage. Strict prior authorization requirements for agents like Saphnelo and belimumab delay treatment until earlier therapies fail or organ involvement worsens. In emerging markets, maintaining standard treatments like hydroxychloroquine and corticosteroids remains difficult without insurance or regular specialist access. Reimbursement alone cannot drive uptake if monitoring infrastructure and specialist availability are inadequate.

Other drivers and restraints analyzed in the detailed report include:

1. Reimbursement Expansion for Specialty Lupus Diagnostics and Therapeutics
2. Rising Demand for Home-Based Administration and Self-Injection Devices
3. Diagnostic Heterogeneity and Delayed Disease Confirmation

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, systemic lupus erythematosus (SLE) accounted for 85.14% of the lupus market, establishing itself as the primary focus for treatment and diagnosis. This dominance is due to SLE's extensive organ involvement, including renal, cardiac, neuropsychiatric, and mucocutaneous systems, which necessitate intensive treatment and complex follow-ups. The 2025 Chinese guidelines for SLE endorsed biologics and JAK inhibitors, marking a shift toward long-term remission and organ protection. SLE patients are more likely to adopt high-value drug regimens and require frequent monitoring, driving market growth.

Cutaneous lupus erythematosus remains a smaller segment, primarily managed through dermatology with topical treatments and lower systemic drug intensity. However, its strategic importance is growing as companies target immune responses aligned with skin-dominant disease biology. Drug-induced and neonatal lupus, while commercially limited, contribute to diagnostic activities and specialist consultations. The push for multidisciplinary care across rheumatology, dermatology, nephrology, and mental health broadens the scope for identifying and managing these subtypes, supporting future demand even in smaller categories.

Biologic drugs held 48.34% of the lupus treatment market in 2025, reflecting their revenue dominance despite limited patient use. Their premium position stems from strong pricing, specialized application in severe cases, and focus on active lupus nephritis and refractory SLE. Roche reported a 46.4% complete renal response rate for obinutuzumab combined with standard therapy, compared to 33.1% for standard therapy alone, validating the high spending on biologics. A small group of high-acuity patients drives significant spending due to the high costs of advanced therapies.

Immunosuppressive drugs are projected to grow at a 9.56% CAGR from 2026 to 2031, making them the fastest-growing treatment category. Voclosporin has revitalized this class with its modern profile and broader regulatory approvals, including its 2024 launch in Japan. Mycophenolate mofetil and tacrolimus are increasingly used in combination regimens under steroid-minimization guidelines. Antimalarial drugs remain foundational in SLE care, while antihypertensives manage cardiovascular complications. Corticosteroid reliance is gradually decreasing as the market shifts toward safer long-term options.

Complete Report Scope:

• By Disease Type
  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus
  • Others
• By Treatment Type
  • Corticosteroids
  • Immunosuppressive Drugs
  • Biologic Drugs
  • Antimalarial Drugs
  • Antihypertensive Drugs
  • Other Treatment Types
• By Diagnosis
  • Laboratory Tests
  • Biopsy
  • Imaging Tests
  • Other Diagnostic Methods
• By End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Diagnostic Laboratories
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America led the lupus market with a 39.25% share, driven by a high density of rheumatology and nephrology specialists, early access to new therapies, and broader reimbursement options compared to other markets. The 2025 ACR guideline and Medicare Part D reform expanded access to biologics, reducing out-of-pocket costs for patients. The U.S. approval of the Saphnelo Pen in April 2026 reduced dependence on infusion centers and improved adherence in community rheumatology settings. In Canada, reimbursement support for obinutuzumab in active lupus nephritis enhanced access to advanced therapies.

Europe remained the second-largest regional contributor to the lupus market, with Germany, the UK, and France generating the highest revenue. The approval of subcutaneous anifrolumab in December 2025 strengthened competition by addressing delivery disadvantages compared to other biologics. The region is also set to benefit from obinutuzumab expansion as regulatory reviews progress, supported by strong late-stage nephritis and broader SLE data. Western Europe leads in biologic access, while Central and Eastern Europe face slower adoption due to inconsistent reimbursement systems.

Asia-Pacific is the fastest-growing region in the lupus market, projected to grow at an 11.20% CAGR from 2026 to 2031. China and Japan drive growth with large patient populations, faster regulatory approvals, and improved specialty access. Japan's approval and launch of voclosporin for lupus nephritis set a precedent for premium therapy adoption. China's 2025 treatment guideline update supports broader biologic use and formalized prescribing in major hospitals. India, South Korea, and Australia contribute to growth, while South America and the Middle East and Africa remain early-stage markets, limited by infrastructure and high out-of-pocket costs.

1. Abbvie
2. Amgen
3. AstraZeneca
4. Aurobindo Pharma
5. Biogen
6. Bristol-Myers Squibb
7. Dr. Reddy's Laboratories
8. Eli Lilly and Company
9. GlaxoSmithKline
10. Hikma Pharmaceuticals
11. Johnson & Johnson
12. Lupin
13. Novartis
14. Pfizer
15. Sanofi
16. Sun Pharmaceuticals Industries
17. Teva Pharmaceutical Industries
18. UCB
19. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence and Earlier Lupus Detection
  • 4.2.2 Shift Toward Targeted Biologics and Steroid-Sparing Treatment
  • 4.2.3 Reimbursement Expansion for Specialty Lupus Diagnostics and Therapies
  • 4.2.4 Rising Demand for Home-Based Administration and Self-Injection
  • 4.2.5 Biomarker-Driven Flare Prediction and Precision Monitoring
  • 4.2.6 Pipeline Expansion in Lupus Nephritis and Refractory SLE
• 4.3 Market Restraints
  • 4.3.1 High Lifetime Treatment Cost and Access Barriers
  • 4.3.2 Diagnostic Heterogeneity and Delayed Disease Confirmation
  • 4.3.3 Infection Risk and Long-Term Safety Concerns With Immunosuppression
  • 4.3.4 Slow Clinical Translation and Narrow Trial Success Rates
• 4.4 Value Chain Analysis
• 4.5 Supply Chain Analysis
• 4.6 Regulatory Landscape
• 4.7 Technological Outlook
• 4.8 Porter's Five Forces Analysis
  • 4.8.1 Bargaining Power of Suppliers
  • 4.8.2 Bargaining Power of Buyers
  • 4.8.3 Threat of New Entrants
  • 4.8.4 Threat of Substitutes
  • 4.8.5 Industry Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Disease Type
  • 5.1.1 Systemic Lupus Erythematosus
  • 5.1.2 Cutaneous Lupus Erythematosus
  • 5.1.3 Others
• 5.2 By Treatment Type
  • 5.2.1 Corticosteroids
  • 5.2.2 Immunosuppressive Drugs
  • 5.2.3 Biologic Drugs
  • 5.2.4 Antimalarial Drugs
  • 5.2.5 Antihypertensive Drugs
  • 5.2.6 Other Treatment Types
• 5.3 By Diagnosis
  • 5.3.1 Laboratory Tests
  • 5.3.2 Biopsy
  • 5.3.3 Imaging Tests
  • 5.3.4 Other Diagnostic Methods
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Clinics
  • 5.4.3 Homecare Settings
  • 5.4.4 Diagnostic Laboratories
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Amgen Inc.
  • 6.3.3 AstraZeneca plc
  • 6.3.4 Aurobindo Pharma Limited
  • 6.3.5 Biogen Inc.
  • 6.3.6 Bristol-Myers Squibb Company
  • 6.3.7 Dr. Reddy's Laboratories Ltd.
  • 6.3.8 Eli Lilly and Company
  • 6.3.9 GSK plc
  • 6.3.10 Hikma Pharmaceuticals PLC
  • 6.3.11 Johnson and Johnson
  • 6.3.12 Lupin Limited
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Sanofi S.A.
  • 6.3.16 Sun Pharmaceutical Industries Limited
  • 6.3.17 Teva Pharmaceutical Industries Limited
  • 6.3.18 UCB S.A.
  • 6.3.19 Zydus Lifesciences Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-space and Unmet-Need Assessment